Skip to main content

Saturn Medic

Clinical Subject Page

Granulomatosis With Polyangiitis (GPA)

Granulomatosis with polyangiitis (GPA), previously called Wegener granulomatosis, is an autoimmune disease in which the body’s immune system attacks small and medium-sized blood vessels.

Also called

Wegener’s granulomatosis — older term

ICD-10

M31.30

Specialty

Pulmonology

Onset

Chronic

Reviewed

July 2026

On This Page

Overview

What is it? An ANCA-associated vasculitis that damages blood vessels. Commonly affects: Nose and sinuses, lungs, kidneys.

This causes inflammation (vasculitis) and granuloma formation

Etiology & Risk Factors

-Etiology :

  • Unknown (idiopathic) in most cases.
  • Often occurs after respiratory tract infections, although the exact cause is not known.
  • It is an autoimmune disease in which PR3-ANCA antibodies activate neutrophils, leading to inflammation and damage of small and medium-sized blood vessels.

-Risk Factors :

  • Age: Most common between 40–60 years.
  • Sex: Men and women are affected equally.
  • Possible trigger: Respiratory tract infections may precede the disease.

Pathophysiology

Unknown trigger (idiopathic, sometimes after respiratory infection) → PR3-ANCAautoantibodies form → PR3-ANCA binds to proteinase-3 (PR3) on neutrophils →Neutrophil activation → Release of inflammatory mediators + neutrophil extracellular traps (NETs) + complement activation → Damage to small and medium-sized blood vessel endothelium → Necrotizing granulomatous vasculitis → Inflammation and tissue injury → ENT disease (sinusitis/rhinitis), lung disease, and rapidly progressive glomerulonephritis (kidney involvement)

Clinical Presentation

General: Fever, weight loss, fatigue

  • ENT (most common): Chronic sinusitis, blocked/bloody nose, ear infections, saddle nose deformity
  • Lungs: Cough, shortness of breath, hemoptysis
  • Kidneys: Hematuria, rapidly progressive glomerulonephritis (RPGN)
  • Skin: Purpura, ulcers
  • Eyes: Conjunctivitis, corneal ulcers

History Taking

  • Do you have chronic sinus pain or a blocked nose?
  • Have you had nosebleeds or bloody nasal discharge? Do you have a persistent cough?
  • Have you coughed up blood (hemoptysis)?
  • Do you feel short of breath?
  • Have you noticed blood in your urine or dark urine?
  • Have you had fever, weight loss, or fatigue?
  • Have you had ear infections or hearing problems?
  • Do you have eye redness, pain, or vision changes?
  • Have you developed a skin rash or ulcers?

Physical Examination

-Look for:

  • General: Fever, weight loss

  • Nose/ENT: Nasal ulcers, saddle nose deformity, bloody/purulent nasal discharge

  • Lungs: Crackles, signs of hemoptysis

  • Skin: Purpura, ulcers

  • Eyes: Conjunctivitis, red eyes, corneal ulcers

  • Mouth: Oral ulcers, strawberry gingivitis

    Key Physical Signs

  • Saddle nose deformity

  • Purpura

     

  • Strawberry gingivitis

  • Conjunctivitis

Investigations of Granulomatosis With Polyangiitis (GPA)

  • Blood tests
  • PR3-cANCA (most important)
  • CBC
  • ESR, CRP
  • Urea, creatinine (renal function)
  • Urine tests
  • Urinalysis: hematuria, proteinuria Urine microscopy: RBC casts
  • Imaging
  • Chest X-ray/CT chest (lung involvement)
  • CT paranasal sinuses (sinus disease)
  • Confirmatory test
  • Biopsy (kidney or lung preferred): necrotizing granulomatous vasculitis

Diagnosis of Granulomatosis With Polyangiitis (GPA)

  • Diagnosis is based on clinical features + investigations, and is confirmed by biopsy.

-Most important diagnostic findings:

  • ENT + lung + kidney involvement (typical clinical picture)
  • PR3-cANCA positive
  • Urinalysis: Hematuria, proteinuria, RBC casts
  • Chest X-ray/CT: Pulmonary nodules or pulmonary hemorrhage Biopsy (gold standard): Necrotizing granulomatous vasculitis

Management of Granulomatosis With Polyangiitis (GPA)

  • Refer to rheumatology (and other specialists as needed). Glucocorticoids (first-line treatment).

-Add an immunosuppressant :

  • Methotrexate (non-severe disease)
  • Rituximab (preferred for severe disease)
  • Cyclophosphamide (alternative for severe disease)
  • -Maintenance therapy : Gradually taper steroids and continue rituximab, methotrexate, or azathioprine.
  • Supportive care: Monitor for treatment side effects and consider Pneumocystis pneumonia prophylaxis.
  • Plasmapheresis: May be considered in selected patients (e.g., with concomitant anti-GBM disease).

Complications

  • Rapidly progressive glomerulonephritis (RPGN) → kidney failure
  • Pulmonary hemorrhage (diffuse alveolar hemorrhage) → life-threatening hemoptysis
  • Pulmonary fibrosis
  • Pulmonary hypertension
  • Cardiac involvement (pericarditis, myocarditis, myocardial infarction)
  • Relapse is common
  • The most serious complications are kidney failure and pulmonary hemorrhage, with diffuse alveolar hemorrhage being a common cause of death.

Prognosis of Granulomatosis With Polyangiitis (GPA)

  • Without treatment: < 20% 1-year survival.
  • With appropriate treatment: Approximately 80% 5-year survival. Diffuse alveolar hemorrhage is a common cause of death.
  • Relapses are common, so long-term follow-up is needed.

Key Points / Clinical Pearls of Granulomatosis With Polyangiitis (GPA)

  • Autoimmune ANCA-associated vasculitis affecting small and medium-sized blood vessels.
  • Mainly affects the nose/sinuses, lungs, and kidneys.
  • PR3-cANCA is the most important antibody.
  • Classic triad: ENT disease + Lung disease + Glomerulonephritis (RPGN).
  • Common symptoms: chronic sinusitis, cough, hemoptysis, hematuria.
  • Biopsy is the gold standard and shows necrotizing granulomatous vasculitis.
  • Main treatment: Glucocorticoids + immunosuppressant (methotrexate, rituximab, or cyclophosphamide).
  • Major complications: Kidney failure and pulmonary hemorrhage.
  • Relapses are common, so long-term follow-up is required.
  • Early diagnosis and treatment greatly improve survival.
  • Rout P, Garlapati P, Qurie A. National Center for Biotechnology Information (NIH). Granulomatosis With Polyangiitis, StatPearls.
  • Hashmi MF, Rout P. National Center for Biotechnology Information (NIH). Microscopic Polyangiitis, StatPearls.
  • National Center for Biotechnology Information (NIH). ANCA-Associated Vasculitis, StatPearls.
  • Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR Recommendations for the Management of ANCA-Associated Vasculitis: 2022 Update. Ann Rheum Dis. 2024. PMID: 36927642.
  • Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022. Ann Rheum Dis 2022;81:315-320.
  • Tan JA, Dehghan N, Chen W, et al. Systematic Literature Review Informing the 2022 EULAR Update: Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis. PMC10364171.